Thyroid remnant ablation in patients with papillary cancer: A comparison of low, moderate, and high activities of radioiodine

Nuclear Medicine Communications

Volumn 30, Issue 4, 2009, Pages 263-269

  Kuna, Sanja Kusacic ^a   Samardzic, Tatjana ^a   Tesic, Vanja ^b   Medvedec, Mario ^a   Kuna, Krunoslav ^c   Bracic, Irena ^a   Despot, Marija ^a   Dodig, Damir ^a  

^a KBC Zagreb   (Croatia)

^b Zagreb Institute of Public Health   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

I 131 activities; Remnant ablation; Thyroid cancer

Indexed keywords

IODINE 131; THYROTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RADIATION DOSE; RADIOISOTOPE THERAPY; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 63149088850     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283299992     Document Type: Article

References (41)

1. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well diferentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685-718.
2. Hurley JR. Management of thyroid cancer: radioiodine ablation, stunning, and treatment of thyroglobulin-positive, (131)I scan-negative patients. Endocr Pract 2000; 6:401-406.
3. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrin Metab 2004; 89:3668-3676.
4. Mazzaferri EL. Thyroid remnant I-131 ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7:265-271.
5. The American Association of Clinical Endocrinologists (AACE), American Association of Endocrine Surgeons (AAES). Medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract 2001; 7:202-220.
6. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25:44-52.
7. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490-1498.
8. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine 131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-1136.
9. Vermiglio F, Violi MA, Finocchiaro MD, Baldari S, Castagna MG, Moleti M, et al. Short-term effectiveness of low-dose radioiodine ablative treatment of thyroid remnants after thyreoidectomy for differentiated thyroid cancer. Thyroid 1999; 9:387-391.
10. Bal CS, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131-I for remnant ablation in patients with different thyroid carcinoma. Cancer 1996; 77:2574-2580.
11. 131. Nucl Med Commun 1996; 17:839-842.
12. Medvedec M, Huic D, Zuvic M, Grosev D, Popovic S, Dodig D, Pavlinovic Z. I-131 total body burden in postsurgical patients with thyroid cancer. Radiol Oncol 1998; 32:281-287.
13. Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005; 26:731-735.
14. Medvedec M. Dosimetric study of radioiodine therapy for thyroid cancer [dissertation]. Zagreb, Croatia:School of Medicine University; 2006.
15. Medvedec M, Dodig D. Has come the day to do away with thyroid remnant ablation targeting 300 gray (Gy)? J Nucl Med 2007; 48 (Suppl 2):16.
16. Medvedec M, Dodig D. High ablation success rate achieved by the lowest I-131 activity to date. J Nucl Med 2008; 49 (Suppl 2):8.
17. Jana S, Abdel-Dayem HM, Young l. Nuclear medicine and thyroid cancer. Eur J Nucl Med 1999; 26: 1528-1532.
18. Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrin Metab 2004; 89:3665-3667.
19. Pacini F, Ladenson W, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91:926-932.
20. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89:1666-1673.
21. 131 I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrin Metab 2007; 92:28-38.
22. Bierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of ablation of thyroid remnants with I-131 in patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984; 25:1287-1293.
23. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1546-1550.
24. Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Reis JS, Purisch S. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer. Ann Nucl Med 2005; 19:247-250.
25. 131I without pre-therapy scanning. Nucl Med Commun 2005; 26:129-132.
26. 131I scintigraphy. Nucl Med Commun 2000; 21:529-532.
27. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003; 24:489-495.
28. 131I in patients with differentiated carcinoma. Nucl Med Commun 2001; 22:1021-1027.
29. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res 2007; 5:87-90.
30. Gawkowska-Suwinska M, Turska M, Roskosz J, Puch Z, Jurecka TB, Handkiewicz-Junak D, et al. Early evaluation of treatment effectiveness using 131-I iodine radiotherapy in patients with differentiated thyroid cancer. Wiad Lek 2001; 54 (Suppl 1):278-288.
31. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131-I dose in differentiated thyroid cancer. Clin Endocrinol 2000; 52:765-773.
32. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32:252-254.
33. McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 1976; 61:52-58.
34. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131-I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005; 153:651-659.
35. 131l doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Nucl Med Commun 2004; 25:1077-1081.
36. Comtois R, Theriault C, Del Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 1993; 34:1927-1930.
37. 131I in treatment of patients with differentiated thyroid cancer? Nucl Med Commun 1996; 17:199-207.
38. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, et al. A comparison of 1850 MBq (50mCi) and 3700 MBq (100mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3542-3546.
39. International Atomic Energy Agency. International basic safety standards for protection against opnizing radiation and for the safety of radiation sources. Vienna: IAEA; 1996.
40. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic I-131 and I-123. Eur J Nucl Med Mol Imaging 2002; 29:783-788.
41. Dietlein M, Dressier J, Eschner W, Grunwald F, Lassmann M, Leisner B, et al. Procedure guidelines for iodine-131 scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46:206-212.